- Moneycontrol /
- Market /
- Pharmaceuticals /
- NINE MONTHLY RESULTS
BSE Live
Feb 17, 14:50Prev. Close
1436.35
Open Price
1440.00
Bid Price (Qty.)
1351.85 (4)
Offer Price (Qty.)
1354.25 (1)
NSE Live
Feb 17, 14:50Prev. Close
1436.90
Open Price
1439.00
Bid Price (Qty.)
1352.05 (27)
Offer Price (Qty.)
1352.70 (2)
| Nine Months Results of Ipca Laboratories (in Rs. Cr.) | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 | |
| Net Sales/Income from operations | 3,362.64 | 2,799.34 | 2,436.46 | 2,405.27 | 2,159.55 | |
| Other Operating Income | -- | -- | -- | 48.68 | 29.23 | |
| Total Income From Operations | 3,362.64 | 2,799.34 | 2,436.46 | 2,453.95 | 2,188.78 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,060.04 | 831.88 | 699.66 | 715.64 | 706.40 | |
| Purchase of Traded Goods | 153.80 | 123.83 | 125.22 | 120.86 | 102.20 | |
| Increase/Decrease in Stocks | -60.08 | -64.93 | 31.61 | 39.05 | 20.29 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 642.91 | 575.42 | 544.22 | 516.19 | 454.12 | |
| Depreciation | 133.31 | 130.27 | 131.21 | 128.22 | 116.85 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 843.93 | 814.64 | 704.00 | 695.28 | 652.13 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 588.73 | 388.23 | 200.54 | 238.71 | 136.79 | |
| Other Income | 51.39 | 40.01 | 28.15 | 16.99 | 16.09 | |
| P/L Before Int., Excpt. Items & Tax | 640.12 | 428.24 | 228.69 | 255.70 | 152.88 | |
| Interest | 12.32 | 12.24 | 17.57 | 23.20 | 57.10 | |
| P/L Before Exceptional Items & Tax | 627.80 | 416.00 | 211.12 | 232.50 | 95.78 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 627.80 | 416.00 | 211.12 | 232.50 | 95.78 | |
| Tax | 103.10 | 70.56 | 29.32 | 88.60 | 36.20 | |
| P/L After Tax from Ordinary Activities | 524.70 | 345.44 | 181.80 | 143.90 | 59.58 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 524.70 | 345.44 | 181.80 | 143.90 | 59.58 | |
| Equity Share Capital | 25.27 | 25.27 | 25.24 | 25.24 | 25.24 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 41.53 | 27.34 | 14.41 | 11.40 | 4.72 | |
| Diluted EPS | 41.51 | 27.34 | 14.41 | 11.40 | 4.72 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 41.53 | 27.34 | 14.41 | 11.40 | 4.72 | |
| Diluted EPS. | 41.51 | 27.34 | 14.41 | 11.40 | 4.72 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- |
